Cargando…

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor

Detalles Bibliográficos
Autores principales:	Duan, Zhenzhen, Zhang, Shengnan, Liang, Heng, Xing, Zikang, Guo, Leilei, Shi, Lei, Du, Lisha, Kuang, Chunxiang, Takikawa, Osamu, Yang, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293319/ https://www.ncbi.nlm.nih.gov/pubmed/32532956 http://dx.doi.org/10.1038/s41392-020-0188-9

Ejemplares similares

Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2020)

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway
por: Du, Lisha, et al.
Publicado: (2021)

Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy
por: Shi, Jing, et al.
Publicado: (2019)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

The Coevolution of IDO1 and AhR in the Emergence of Regulatory T-Cells in Mammals
por: Grohmann, Ursula, et al.
Publicado: (2015)

Serum Response Factor-Regulated IDO1/Kyn-Ahr Pathway Promotes Tumorigenesis of Oral Squamous Cell Carcinoma
por: Xu, Mingyan, et al.
Publicado: (2023)

Tryptophan Feeding of the IDO1-AhR Axis in Host–Microbial Symbiosis
por: Zelante, Teresa, et al.
Publicado: (2014)

AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives
por: Turski, Waldemar A., et al.
Publicado: (2020)

Regulation of IDO2 by the Aryl Hydrocarbon Receptor (AhR) in Breast Cancer
por: Kado, Sarah Y., et al.
Publicado: (2023)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

Synergistic effect of endurance training and nettle leaf extract on the IDO1-KYN-AHR pathway homeostasis and inhibiting of liver toxicity in rats with STZ-induced diabetes
por: Haghshenas, Rouhollah, et al.
Publicado: (2023)

TDO2 Promotes the EMT of Hepatocellular Carcinoma Through Kyn-AhR Pathway
por: Li, Lei, et al.
Publicado: (2021)

Smek1 deficiency exacerbates experimental autoimmune encephalomyelitis by activating proinflammatory microglia and suppressing the IDO1-AhR pathway
por: Duan, Ruo-Nan, et al.
Publicado: (2021)

The IDO–AhR Axis Controls Th17/Treg Immunity in a Pulmonary Model of Fungal Infection
por: de Araújo, Eliseu Frank, et al.
Publicado: (2017)

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1
por: Brincks, Erik L., et al.
Publicado: (2020)

Correction: Smek1 deficiency exacerbates experimental autoimmune encephalomyelitis by activating proinflammatory microglia and suppressing the IDO1-AhR pathway
por: Duan, Ruo-Nan, et al.
Publicado: (2023)

Comparison of moderate-intensity continuous training and high-intensity interval training effects on the Ido1-KYN-Ahr axis in the heart tissue of rats with occlusion of the left anterior descending artery
por: Nori, Pouria, et al.
Publicado: (2023)

Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance
por: Zhang, Xin, et al.
Publicado: (2021)

The Gut Microbiota Activates AhR Through the Tryptophan Metabolite Kyn to Mediate Renal Cell Carcinoma Metastasis
por: Dai, Guoyu, et al.
Publicado: (2021)

Cancer Associated Fibroblasts Promote Renal Cancer Progression Through a TDO/Kyn/AhR Dependent Signaling Pathway
por: Chen, Li-bo, et al.
Publicado: (2021)

Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells
por: Liu, Yuying, et al.
Publicado: (2017)

Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFNγ-Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma
por: Meireson, Annabel, et al.
Publicado: (2021)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

IDO1 is an Integral Mediator of Inflammatory Neovascularization
por: Mondal, Arpita, et al.
Publicado: (2016)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

The Landscape of AhR Regulators and Coregulators to Fine-Tune AhR Functions
por: Gargaro, Marco, et al.
Publicado: (2021)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

Serotonin Modulates AhR Activation by Interfering with CYP1A1-Mediated Clearance of AhR Ligands
por: Manzella, Christopher R., et al.
Publicado: (2020)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

Coactivator Recruitment of AhR/ARNT1
por: Endler, Alexander, et al.
Publicado: (2014)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

(Acetylacetonato)dibromido[2,2-diphenylhydrazin-1-ido(1−)][2,2-diphenylhydrazin-1-ido(2−)]molybdenum(VI)
por: Bustos, Carlos, et al.
Publicado: (2011)

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
por: Litzenburger, Ulrike M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7k820j2todoc51qcgjn41oanj7